(10)Commission Directive 2011/6/EUnote included buprofezin in Annex I to Directive 91/414/EEC as an active substance until 31 January 2021 and it was subsequently included in Part A of the Annex to Implementing Regulation (EU) No 540/2011. The approval of buprofezin was extended four times, most recently by Commission Implementing Regulation (EU) 2025/1489note until 15 December 2026.
Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.